Press ReleasesShow only this topic 11/08November 14, 2008 Patheon and Solvias AG Announce Strategic Alliance to Provide Integrated Development Services Patheon (TSX:PTI), and Solvias AG, are pleased to announce a global alliance to offer integrated development services to pharmaceutical and biotechnology companies. This alliance combines Patheon’s experience and expertise in formulation development with Solvias AG’s reputation of excellence in pre-formulation and solid state chemistry. 10/08October 29, 2008 Solvias Announces Construction of cGMP Kilo Lab in Basel (Switzerland) Solvias has announced the construction of its new kg-scale cGMP manufacturing plant in Basel, which is planned to be operational within Q2/09. The facility will complement the existing state-of-the-art kilo lab by rapid and cost-effective manufacturing of materials destined for use in clinical studies for phase I/IIa, and by providing flexible access to state-of-the-art 30l– 100l multi-purpose reactors capable of running reactions from - 60 to + 200°C. Wet processing will be carried out in a reactor room, while dry processing will be performed in a separate finishing area. 09/08September 30, 2008 Solvias Has Acquired an Exclusive License for Homogeneous Catalysis Technology from Evonik Solvias AG, Basel (Switzerland) has acquired an exclusive license from Evonik Degussa GmbH, Essen (Germany) to develop, manufacture, and market the catASium® and cataCXium® ligand product lines. The new license will enhance the status of Solvias as one of the most capable excellence centers for homogeneous catalysis and High Throughput Screening (HTS). 3/08March 25, 2008 Record Sales for Solvias AG 2007 was a record year for Basel-based Solvias AG, which increased its sales by 20%. Total revenue including licensing increased by CHF 10.5 million to CHF 63.5 million. Sales from international business topped those in Switzerland for the first time. 2/08February 6, 2008 Solvias Constructs New Building in Kaiseraugst The Board of Directors of Solvias AG in Basel has decided to build a new headquarters in Kaiseraugst. The preliminary contract to buy the land was signed at the start of January 2008, with construction work due to start in a few months’ time. 5/07May 9, 2007 Prof. Armido Studer Wins the 2007 Solvias Ligand Contest Prof. Armido Studer (Münster, Germany) convincingly won the 2007 contest with his significant contribution to the field of homogeneous catalysis using Solvias ligands. 3/07March 23, 2007 Solvias Reports Good Growth Strong demand for our products and services in 2006 coupled with a sustained increase in capacity utilization led to a 9% rise in sales over the previous year. The American market recorded the largest sales growth, with a double-digit percentage increase. 7/06July 6, 2006 Solvias Acquires Licence for Chiral Catalysis Technology from Roche Solvias has licensed the rights to manufacture, market, and distribute the well-known MeOBIPHEP catalyst technology from Roche. 5/06May 9, 2006 Solvias Ligand Contest 2006 with Two Winners 2006, the jury has awarded the first prize jointly to two winners. Prof. Ken Tanaka (Tokyo, Japan) and Prof. Michael J. Krische (Austin, Texas, USA) are honored in recognition of their significant contributions in the area of asymmetric catalysis and the application of Solvias ligands. 3/06March 30, 2006 A Successful 2005 for Solvias Sales growth in Europe and North America, as well as disproportionate growth in licensing revenue, led to an increase in total revenues of around 10% to 52 million Swiss francs. Along with the rise in demand for services and products there was a marked increase in the utilization of capacities. 2/06February 15, 2006 Solvias Acquires Exclusive Licence for Highly Efficient CN-Coupling Technology Using Josiphos Ligands (Buchwald-Hartwig Amination) from Yale University Solvias has exclusively licensed a highly efficient CN-coupling technology for aromatic and heteroaromatic chlorides, bromides and sulfonates with amines and imines from Yale University (US patents 5,977,361 and 6,235,938 B1). The licensing of this CN-coupling technology represents a natural extension of Solvias’s technology portfolio and is immediately available to our customers to support industrial-scale manufacturing. February 15, 2006 Solvias to Introduce High Throughput Catalysis Screening Services Solvias launches its first full-scale High-Throughput Catalysis Screening Service for asymmetric homogeneous hydrogenation. The fully automated system utilizes standard 96-well plates combined with analysis by supercritical fluid chromatography (SFC), high-performance liquid chromatography (HPLC), and gas chromatography (GC). 3/05March 23, 2005 Solvias Posts Substantial Sales Growth With a 14% increase in 2004 total revenue, Solvias is back on track for growth. Sales grew by 6% in Switzerland, were as an overproportional increase was also recorded in the European markets. In the United States sales also outperformed expectations, with growth remaining strong in 2005. 1/05January 18, 2005 Solvias Signs Research and Development Agreement with Pfizer Inc. Solvias AG announced 2005 the execution of a research and development agreement with Pfizer Inc., Global Research and Development. This agreement will allow Pfizer to access Solvias’s chiral ligand and asymmetric catalysis technology for the process development and manufacture of single enantiomer drugs. 10/04October 8, 2004 BASF Signs Cooperation Agreement with Solvias New alliance enhances BASF’s technology platform for optically active intermediates. BASF has signed a cooperation agreement with Solvias AG, Basel, Switzerland. In cooperation with Solvias, BASF will use these ligands to manufacture optically active intermediates for the life sciences industry. |
